Determining the Comparative Value of Pharmaceutical Risk-Sharing Policies in Non –Small Cell Lung Cancer Using Real-World Data

Risk-sharing arrangements (RSAs) can be used to mitigate uncertainty about the value of a drug by sharing the financial risk between payer and pharmaceutical company. We evaluated the projected impact of alternative RSAs for non –small cell lung cancer (NSCLC) therapies based on real-world data.

Source: Value in Health - October 25, 2018 Category: International Medicine & Public Health Authors: Marscha S. Holleman, Carin A. Uyl-de Groot, Stephen Goodall, Naomi van der Linden Source Type: research